Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Relapse after HSCT 2021 | Challenges of CAR-T therapy for CLL

Peter Dreger • 5 Oct 2021
Relapse after HSCT 2021
B-Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia CAR-T

Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, talks on the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with chronic lymphocytic leukemia (CLL). Prof. Dreger explains that patients with specific genetic aberrations indicative of a poor prognosis, such as tp53 alterations and complex karyotypes, are good candidates for cellular therapy. Nevertheless, due to the immunosuppressive properties of CLL cells, CAR-T therapy is not as effective as in other B-lymphoid malignancies. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

More from Peter Dreger

1:33
Management of relapse after CAR-T in patients with B-cell lymphoma
Peter Dreger • 5 Oct 2021
1:56
Management of relapse post-alloHSCT in patients with B-cell lymphoma
Peter Dreger • 5 Oct 2021
1:21
The role of transplant in the era of new treatments for lymphoma and CLL
Peter Dreger • 18 Apr 2016

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals